Neumora Therapeutics is trading at $0.45, up 6.46%, with no clear company-specific catalyst identified.
- The provided price context shows a 20.45% regular-session gain on October 15, followed by a smaller pre-market rise.
- An October 16 report described an analyst downgrade after news about Johnson & Johnson’s depression-drug trial; this does not explain the gain.
- Broad-market indicators are modestly positive, but no sector or market-wide reason is established. Pre-market volume was unavailable.